Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): A randomized, multicenter, double-blind study (CN138-392)

Bipolar Disorders

Volumn 14, Issue 1, 2012, Pages 41-53

  Carlson, Berit X ^a   Ketter, Terence A ^b   Sun, Wei ^a   Timko, Karen ^a   Mcquade, Robert D ^c   Sanchez, Raymond ^c   Vester Blokland, Estelle ^a   Marcus, Ronald ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Aripiprazole; Bipolar disorder; Efficacy; Safety

Indexed keywords

ARIPIPRAZOLE; LAMOTRIGINE; LORAZEPAM; PLACEBO;

ADULT; AGITATION; AKATHISIA; ANXIETY DISORDER; ARTICLE; BACKACHE; BIPOLAR I DISORDER; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MANIA; MONTGOMETRY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SEDATION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SUICIDE; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WEIGHT CHANGE; WEIGHT GAIN; XEROSTOMIA; YOUNG MANIA RATING SCALE;

ADULT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; QUINOLONES; RECURRENCE; TREATMENT OUTCOME; TRIAZINES;

EID: 84856846619     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2011.00974.x     Document Type: Article

References (43)

1. Thase ME. Maintenance therapy for bipolar disorder. J Clin Psychiatry 2008; 69: e32.
2. Begley CE, Annegers JF, Swann AC et al. The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoeconomics 2001; 19: 483-495.
3. Suppes T, Dennehy EB, Hirschfeld RM et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005; 66: 870-886.
4. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: revised second edition - recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23: 346-388.
5. Grunze H, Vieta E, Goodwin GM et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009; 10: 85-116.
6. Yatham LN, Kennedy SH, Schaffer A et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009; 11: 225-255.
7. Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010; 71: 130-137.
8. Suppes T, Vieta E, Liu S, Brecher M, Paulsson B. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (Trial 127). Am J Psychiatry 2009; 166: 476-488.
9. Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008; 109: 251-263.
10. Tohen M, Chengappa KNR, Suppes T et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004; 184: 337-345.
11. Macfadden W, Alphs L, Haskins JT et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord 2009; 11: 827-839.
12. Keck PE, Marcus R, Tourkodimitris S et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160: 1651-1658.
13. Sachs G, Sanchez R, Marcus R et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006; 20: 536-546.
14. Vieta E, T'joen C, McQuade RD et al. Adjunctive aripiprazole in bipolar mania partially non-responsive to valproate/lithium: a placebo-controlled study (CN138-134). Am J Psychiatry 2008; 165: 1316-1325.
15. Keck PE, Calabrese JR, McQuade RD et al. A randomized, double-blind, placebo-controlled 26-Week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006; 67: 626-637.
16. Keck PE, Calabrese JR, McIntyre RS et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007; 68: 1480-1491.
17. Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302: 381-389.
18. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur J Pharmacol 2002; 441: 137-140.
19. Shapiro DA, Renock S, Arrington E et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacol. 2003; 28: 1400-1411.
20. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 2004; 483: 45-53.
21. Stark AD, Jordan S, Allers KA et al. Interaction of the novel antipsychotic aripiprazole with 5-HT(1A) and 5-HT (2A) receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacol 2007; 190: 373-382.
22. Tadori Y, Forbes RA, McQuade RD, Kikuchi T. Characterization of aripiprazole partial agonist activity at human dopamine D(3) receptors. Eur J Pharmacol 2008; 597: 27-33.
23. Marcus R, Khan A, Rollin L et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord 2011; 13: 133-144.
24. Vieta E, Owen R, Baudelet C, McQuade RD, Sanchez R, Marcus RN. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study. Curr Med Res Opin 2010; 26: 1485-1496.
25. Bowden C, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392-400.
26. Calabrese JR, Bowden CL, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013-1024.
27. Goodwin GM, Bowden CL, Calabrese JR et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004; 65: 432-441.
28. Ketter TA, Brooks JO, Hoblyn JC et al. Effectiveness of lamotrigine in bipolar disorder in a clinical setting. J Psychiatr Res 2008; 43: 13-23.
29. van der Loos MLM, Mulder P, Erwin GThM Hartong et al. Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design. Bipolar Disord 2011; 13: 111-117.
30. van der Loos ML, Mulder PG, Hartong EG et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70: 223-231.
31. Ketter TA, Johnson K, Childers M, Srivastava S, Brooks JO, Hoblyn JC. The long-term effectiveness of quetiapine plus lamotrigine therapy in bipolar patients. Bipolar Disord 2009; 11(Suppl. 1): 53.
32. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435.
33. Guy W. Abnormal Involuntary Movement Scale (AIMS). US Department of Health Education and Welfare ECDEU Assessment Manual for Psychopharmacology. Rockville: National Institute of Mental Health, 1976: 534-537.
34. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-676.
35. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11-19.
36. Walter SD. Number needed to treat (NNT): estimation of a measure of clinical benefit. Stat Med 2001; 20: 3947-3962.
37. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999; 319: 1492-1495.
38. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Statistical Ass 1958; 53: 457-481.
39. Tohen M, Calabrese JR, Sachs GS et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006; 163: 247-256.
40. Tohen M, Zarate CA Jr, Hennen J et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry 2003; 160: 2099-2107.
41. Sicras-Mainar A, Blanca-Tamayo M, Rejas-Gutierrez J, Navarro-Artieda R. Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: a cross-sectional assessment of a primary health care database. Eur Psychiatry 2008; 23: 100-108.
42. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001; 46: 273-281.
43. Jakovljevic M, Crncevic Z, Ljubicic D, Babic D, Topic R, Saric M. Mental disorders and metabolic syndrome: a fatamorgana or warning reality? Psychiatr Danub 2007; 19: 76-86.